A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor

Grants

Funding Acknowledgements

Supported by institutional funding from Box Hill MS Research Fund and the Royal Melbourne Hospital Neuroscience Foundation.A. van der Walt has received travel support from Bayer Australia and Sanofi-Aventis. She receives a scholarship (520676) from the National Health and Medical Research Council (NHMRC) of Australia. She has received unrestricted grants from Bayer Australia and Biogen Idec. She was awarded postgraduate research grants from GlaxoSmithKline, Sanofi-Aventis, and Merck Serono. She is an investigator on a National Multiple Sclerosis Society (USA) Project Grant (RG4211A4/2). S. Sung has received unrestricted grant support from Pfizer Australia and Allergan Australia. T. Spelman has received travel support from Biogen Idec Australia. M. Marriott has served on scientific advisory boards for Bayer Australia. He has received travel support from Biogen Idec, Merck Serono, and Bayer Australia. S. Kolbe has received travel support from Merck Serono. He has received an MS Research Australia postdoctoral fellowship. He is an investigator on a National Multiple Sclerosis Society (USA) Project Grant (RG4211A4/2). P. Mitchell performs neuroimaging in his clinical practice (75%) and bills for these procedures. He was funded by the NHMRC (# 284354) for a vertebroplasty trial, receives research support from Boston Scientific, and was primary investigator (PI) on Matrix and Platinum Science endovascular coiling study in Australia. He has received honoraria for serving on scientific boards for Cordis Johnson & Johnson and Boston Scientific. He is on the steering committee and is the neurointerventional PI for the Talecris Intra-arterial Plasmin study (Protocol No. T05018-1001) as well as the neurointerventional PI on the IMS3 stroke trial. A. Evans has received honoraria from Novartis for giving presentations and providing consultancy services. He has participated in scientific advisory board meetings for Novartis, UCB Pharma, Allergan, and Boehringer Ingelheim. He has received conference travel support from Boehringer Ingelheim. H. Butzkueven has served on scientific advisory boards for Biogen Idec, Novartis, and Sanofi-Aventis and has received conference travel support from Novartis, Biogen Idec, and Sanofi-Aventis. He serves on steering committees for trials conducted by Merck Serono, Biogen Idec, and Novartis. Prof. Butzkueven has received research support from Merck Serono, Novartis, and Biogen Idec in his capacity as honorary chair of the MSBase Foundation. He is on the editorial board of Multiple Sclerosis International. He is the recipient of a NHMRC Career Development Award (628856), NHMRC Project Grants (566513, 628799, and 1009757), NHMRC Centre of Excellence Award (1001216), an Australian Research Council Linkage Grant (LP110100473) and National Multiple Sclerosis Society (USA) Project Grants (RG3850A3/1 and RG4211A4/2). Go to Neurology.org for full disclosures.